Dexmedetomidine is a potent alpha(2)-adrenoceptor agonist with 8 times high
er affinity for the alpha(2)-adrenoceptor than clonidine.
Dexmedetomidine has shown sedative, analgesic and anxiolytic effects after
intravenous administration to healthy volunteers or postsurgical patients i
n the intensive care unit,
Dexmedetomidine produced a predictable haemodynamic decline (dose-dependent
ly decreased arterial blood pressure and heart rate) in postsurgical patien
ts coinciding with reductions in plasma catecholamines.
In phase III clinical trials, dexmedetomidine 0.2 to 0.7 mu g/kg/h produced
clinically effective sedation and significantly reduced the analgesic requ
irements of postsurgical ventilated intensive care unit patients, There was
no clinically apparent respiratory depression after cessation of assisted
ventilation.
Dexmedetomidine produced rapid and stable sedation in postsurgical ventilat
ed patients while maintaining a high degree of patient rousability and anxi
ety reduction.
Dexmedetomidine was well tolerated in phase III studies, The most frequentl
y observed adverse events were hypotension, bradycardia and nausea.